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Abstract
Several growth hormone-independent 25-31,000 kD insulin-
like growth factor binding proteins (IGF-BPs) have been iden-
tified in plasma, extravascular fluids, and various cell-condi-
tioned media. Cultured human decidual cells release three
IGF-BPs with 24,000, 30,000, and 34,000 Mr. Using ligand
blot analysis and an RIA for the 30,000-M, form (IGF-BP-1),
we examined the effects of IGF-I (10-1,000 ng/ml), insulin
(10-10,000 ng/ml), and relaxin (10-250 ng/ml) on decidual
cell IGF-BP release after 120 h of hormone exposure. IGF-I
inhibited release of both IGF-BP-1 and the 24,000 Mr form.
Inhibition of IGF-BP-1 release was noted after 48 h of treat-
ment and was progressive throughout the subsequent 120 h.
Insulin stimulated a fourfold increase in release of the 24,000-
M, protein while inhibiting IGF-BP-1 release comparable to
IGF-I. a-IR3, a monoclonal antibody to the IGF-I receptor,
blocked - 33% of the IGF-I response but had no effect on
insulin-mediated IGF-BP-1 inhibition. Relaxin stimulated a
2.4-fold increase in release of the 24,000-M, form and a 16-
fold increase in the 30,000-Mr protein after 120 h. Stimulation
of the 30,000-M, protein was inhibited by the addition of cy-
cloheximide (50 gg/ml). Both IGF-I and insulin also blocked
the relaxin-mediated increase in IGF-BP-1. These studies
suggest that three structurally related proteins differentially
regulate IGF-BP secretion. possibly via activation of distinct
receptor subtypes. (J. Clin. Invest. 1990. 86:878-883.) Key
words: decidua * insulin-like growth factors * IGF-BPs * relaxin
Introduction
The insulin-like growth factors (IGFs)' are ubiquitous peptides
that diversely influence cellular proliferation and differentia-
tion. These peptides circulate in plasma bound to specific car-
rier proteins (1-5). The IGF-binding proteins (IGF-BPs) serve
not only to transport IGFs in the circulation (5, 6), but also to
prolong their serum half-life (4, 6), modulate tissue specificity
for IGF action (4, 7, 8), and potentiate or neutralize various
biologic actions of the IGFs (9-12).
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Recent studies have shown that at least three structurally
distinct forms of IGF-binding proteins exist. The first is a gly-
coprotein with an estimated molecular mass of 53,000 D
(IGF-BP-3) (13-15). It forms a complex in blood with an acid
labile protein. This 150,000-D complex is thought to be the
major carrier of IGF-I and IGF-II in the circulation. The other
two proteins are not glycosylated, have lower mol wt estimates
(31,000, IGF-BP-2 [16] and 25,000, IGF-BP-l [17]), and have
been purified from amniotic fluid or conditioned media of
distinct cell types (11, 18-22). These proteins are minor car-
riers in blood and their binding capacity in other extravascular
fluids relative to IGF-BP-3 is unknown. Several other forms of
IGF-BP appear to be present in extravascular fluids (23-25).
These have been defined by unique M, estimates, failure to
react with antisera specific for one of the known IGF-BPs, or a
unique set offactors that control their secretion. They have not
been structurally characterized.
At present, the factors regulating IGF-BP secretion are not
completely defined. Plasma concentrations of IGF-BP-3 are
growth hormone dependent while plasma concentrations of
IGF-BP- 1 and 2 are elevated in growth hormone-deficient
states (5, 26). Tissue-specific regulation of binding protein se-
cretion by various growth factors and steroid hormones has
also been recently demonstrated in a few in vitro systems (27).
Specifically, stimulation of IGF-BP secretion by IGF-I has
been demonstrated in liver explants (28), myocytes (29), and
human fibroblasts (21). Similarly, insulin has been shown to
stimulate the release of IGF-BPs in myocytes but is inhibitory
in Hep G2 cultures (29, 30), suggesting that there may be cell
type-specific patterns for regulation of IGF-BP secretion.
Recent studies have demonstrated that these binding pro-
teins are secreted by human decidual tissue (31-33). We have
previously demonstrated that human decidual cell cultures se-
crete three distinct IGF-BPs of 24,000, 30,000, and 34,000 Mr
(34). The 30,000-M, form appears to be immunologically in-
distinguishable from the 25,272-D form (IGF-BP-1), first puri-
fied from amniotic fluid (BP-28 [20], placental protein 12
[32]), and later demonstrated in human endometrium (33, 35,
36) and conditioned media of decidual explants (31), human
hepatoma cells (37), and fibroblasts (21). In this study we have
examined the effects of IGF-I, insulin, and relaxin, three
structurally related proteins, on the release of IGF-BPs from
human decidual cells. The results demonstrate differential reg-
ulation of decidual IGF-BP secretion by these three growth
factors.
Methods
Cell preparation. Term placentas were obtained within 1 h of uncomn-
plicated deliveries at either Duke University Medical Center or Dur-
ham County General Hospital, Durham, NC. In each instance, in-
formed consent was obtained from the patient with permission of the
Human Investigations Committee at Duke University Medical Center.
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Decidual tissue adherent to the chorion of the placental membranes
was manually stripped away and rinsed in normal saline. The decidual
tissue was then enzymatically digested in buffered RPMI 1640 culture
media (Gibco Laboratories, Grand Island, NY) containing 0.1% Col-
lagenase (Worthington Biochemical Corp., Freehold, NJ), 0.1% Hyal-
uronidase (Sigma Chemical Co., St. Louis, MO), 0.1% trypsin inhibi-
tor, and 0.0005% deoxyribonuclease I (Worthington Biochemical
Corp.). The digestion mixture was filtered through a 150-MM mesh
nytex cloth (Swiss nylon monofilament; Tetko Inc., Elmsford, NY)
and the resulting cell suspension was pelleted, washed, and layered
onto linear density gradients of40% Percoll (Sigma Chemical Co.). As
previously demonstrated (38), an enriched fraction of prolactin-pro-
ducing decidual cell sediments at a density of 1.017-1.044 g/ml after
centrifugation at 800 g for 20 min. Viability ofcells from this band was
determined by trypan blue exclusion. 1 million cells/ml were then
plated in collagen-coated (Vitrogen 100; Collagen Corp., Palo Alto,
CA) 24-well tissue culture clusters (Costar Data Packaging Corp.,
Cambridge, MA) in RPMI 1640 medium supplemented with 10% fetal
calf serum (Hyclone Laboratories, Logan, UT), 50 ,ug/ml gentamicin
(Elkins-Sinn Inc., Cherry Hill, NJ), 25 Mu/ml penicillin (Gibco Labora-
tories), 25 M/ml streptomycin (Gibco Laboratories), and 5 Mg/ml Am-
photericin B (Sigma Chemical Co.). Cells were allowed to attach to the
matrix during a 48-h incubation at 370C in a humidified atmosphere
of95% air/5% CO2.
Experimental design. Cell cultures were maintained an additional
120 h in either control medium supplemented only with antibiotics, or
media additionally supplemented with one or more of the following:
(a) human recombinant IGF-I (10-1,000 ng/ml; Fujisawa Pharma-
ceutical Co., Osaka, Japan); (b) human semi-synthetic regular insulin
(10-10,000 ng/ml, Novolin; Squibb Novo, Princeton, NJ); (c) porcine
relaxin (National Institutes of Health, Bethesda, MD); (d) a-IR3 (100
nM), a monoclonal antibody to the type I IGF receptor, purified by
sequential precipitation in 18 and 15% sodium sulfate (39) (provided
by J. J. Van Wyk, University of North Carolina, Chapel Hill, NC); or
(e) 1.0 MM cycloheximide (Sigma Chemical Co.). Conditioned me-
dium was sampled daily and exchanged completely with fresh media
containing the appropriate treatments. IGF-BP concentrations in the
media were assayed using an RIA specific for IGF-BP- 1, the amniotic
fluid binding protein, as previously described (40). As demonstrated by
Hossenlopp, IGF-BP does not appreciably bind to collagen (41). The
assay measurements represent the mean of duplicate determinations
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that were obtained from triplicate cultures. Each point therefore is the
mean of six determinants.
After 120 h of hormone exposure, cells from selected experiments
were gently harvested from the collagen matrix using collagenase, and
the DNA content of harvested cells was determined fluorometrically
using methods described by La Barca and Paigin (42).
Ligand blotting. A 20-,ul aliquot ofconditioned media was added to
Laemmli sample buffer (43) and heated to 60°C for 10 min. Samples
were then clarified by centrifugation and electrophoresed through a
12.5% SDS polyacrylamide gel. Separated proteins were transferred to
nitrocellulose filters using a Janssen semi-dry electroblotter. The blots
were then probed with 100,000 cpm/cm3 1251-IGF-I according to
methods described by Hossenlopp (41). '25I-IGF-I (specific activity
150-250 MCi/Mg) was prepared by a previously described method (44)
and was a gift from L. Underwood (University of North Carolina,
Chapel Hill, NC). Binding protein bands were then visualized by auto-
radiography following 3-5 d of exposure. Changes in band intensity
were quantified by scanning densitometry using a Hoefer 350 scanning
analysis program (Hoefer Scientific Instruments, San Francisco, CA).
Band intensity changes were linear over the scanning range used in this
study when pure IGF-BP- I was used as a standard.
Statistics. All experimental variables were tested in triplicate and
repeated using cell cultures from at least three different pregnancies.
Multivariant statistical analysis was performed using the analysis of
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Figure 1. Inhibition of IGF-BP-1 release by IGF-I and insulin.
Monolayer cultures ofhuman decidual cells were exposed for 120 h
to control media (--*) or media supplemented with 100 ng/ml
IGF-I (i ---.) or insulin (A---A). Samples of conditioned media were
collected from successive 24-h periods and assayed for IGF-BP. Each
point represents the mean±SEM of triplicate cultures. At 48 h, the P
value for the inhibition of IGF-BP-I by IGF-I and insulin was < 0.01
in each instance. At 72-120 h, the P value was < 0.001 at each time.
In the experiment depicted in Fig. 1, decidual cells were ex-
posed to either IGF-I (100 ng/ml) or insulin (100 ng/ml) for
120 h. During the first 24-h period, IGF-BP-1 concentrations
in the media of control and treated cultures were similar (data
not shown). However, between 48 and 120 h, cells exposed to
either growth factor released significantly less IGF-BP-1 than
control cultures. The degree of inhibition of IGF-BP-1 secre-
tion increased over time.
The inhibitory effects of IGF-I and insulin were concen-
tration dependent (Fig. 2). Half-maximal inhibition of IGF-
BP- 1 was achieved at IGF-I, and insulin concentrations of 25
ng/ml and maximal inhibition occurred at concentrations of
100 ng/ml or greater for both hormones. In this and in several
other experiments insulin produced less absolute suppression
ofbinding protein activity, though the pattern ofIGF-BP inhi-
bition by these two growth factors was indistinguishable.
At supraphysiologic concentrations (e.g., 1,000-10,000
ng/ml), insulin binds to the type I IGF receptor. In experi-
ments designed to determine whether IGF-I and insulin share
a common receptor pathway for inhibition of IGF-BP- I secre-
tion, we exposed decidual cultures to a-IR3, a monoclonal











Figure 3. Effect of
a-IR3, a monoclonal
antibody to the type I
IGF receptor, on inhibi-
tion of decidual IGF-
BP-l release. Cultured
decidual cells were ex-
posed for 96 h to either
E -I<g EL control medium or me-dium supplemented
CONaR* IQ-I OF-I INs INsCON *Ea lop- + with IGF-I (100 ng/ml),
aIas am insulin (100 ng/ml),
a-IR3 (100 nM), or the
combination of a-IR3 with each growth factor. Each point represents
the mean±SEM of triplicate cultures. *P < 0.01.
antibody to the type I IGF receptor that inhibits IGF-I binding
and type I IGF receptor mediated effects in other systems (39).
As shown in Fig. 3, approximately one-third ofthe IGF-I effect
could be inhibited by a-IR3 exposure. In contrast, the combi-
nation of insulin plus a-IR3 produced results that were not
statistically different from those after treatment with insulin
alone.
In contrast to IGF-I and insulin, relaxin (100 ng/ml) stimu-
lated a marked increase in the release of IGF-BP-1 (Fig. 4).
Relaxin-treated cultures released 125±4, 369±25, 1,340±64,
and 2,336±259% more IGF-BP than control cultures after
48-120 h of exposure, respectively. Relaxin-mediated effects
were also dose dependent (Fig. 5). The half-maximal and
maximal effective concentrations for stimulated release of
IGF-BP were 25 and 100 ng/ml, respectively. In addition, the
basal and relaxin stimulated release ofIGF-BP- 1 was inhibited
by exposure to cycloheximide (Fig. 6). This suggests that the
increase in assayable IGF-BP-1 is primarily due to newly syn-
thesized protein.
Comparing Figs. 4 and 1, significant variability in basal
IGF-BP secretion was observed between different experiments.
The etiology ofthis discrepancy is unclear though it is possible
that some variability in the state ofcellular differentiation or in
the purity of a cell population existed among different cell
preparations. Despite this discrepancy in basal secretion rates,
effects of IGF-I, insulin, and relaxin were qualitatively repro-
ducible in all experiments.
To exclude the possibility that the changes in IGF-BP-I
concentrations were the result of changes in cell number, we
assayed the DNA content ofcultures after 120 h ofexposure to
IGF-I, insulin, or relaxin (100 ng/ml). Total DNA/million
300-* Figure 4. Stimulation of
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HOURS Each point represents
the mean±SEM of triplicate cultures. This is compared with the
IGF-BP- I release from untreated control cultures (.-). *P < 0.01;











IGF-BP-l release in re-
sponse to relaxin. Re-
laxin concentrations
ranging from 0-250
ng/ml were added to
confluent decidual cul-
tures over a 96-h pe-
riod. Each point repre-
sents the mean±SEM of
triplicate cultures as-
250 sayed for IGF-BP- I at
96 h.
cells was not statistically different from control cultures
(3.7±0.3; MEAN±SEM) after IGF-I (3.6±0.2), insulin
(4.0±0.3), or relaxin (4.4±0.1,ug) treatment.
To determine whether IGF-I, insulin, or relaxin also regu-
late release of the 24,000 and 34,000 Mr IGF-BPs in a manner
analogous to IGF-BP-1, conditioned media from treated cul-
tures were compared by ligand blot analysis. A ligand blot of
conditioned media from decidual cells exposed to 100 ng/ml
IGF-I, insulin, or relaxin for 120 h is shown in Fig. 7. Three
bands with Mr estimates of 24, 30, and 34,000 were detected in
control medium (lane 1). The 30,000-Mr band corresponds to
IGF-BP-l as determined by Western blotting. IGF-I (lane 2)
inhibited release ofboth the 24- and 30-kD binding proteins by
83 and 78%, respectively (densitometric analysis). In contrast,
insulin (lane 3) inhibited release of the 30,000 Mr IGF-BP but
stimulated a fourfold increase in intensity of the 24,000-M,
protein band (2,107±201-8,696±1,347 U). Neither IGF-I nor
insulin appreciably affected release of the 34,000-Mr form.
Relaxin (lane 4) stimulated a 2.4-fold increase in the 24,000-
Mr form and a 16-fold increase in the 30,000-Mr protein. It
appeared to have little or no effect on the 34,000 Mr IGF-BP.
We next determined if IGF-I or insulin could inhibit re-
laxin-stimulated release of IGF-BP-1. Cultures were exposed
to the combination of IGF-I or insulin + relaxin. As shown in
Fig. 8, relaxin induced a 2.5-fold increase in IGF-BP- 1 secre-
tion. The addition of either IGF-I or insulin, however, com-
pletely blocked the stimulated release of binding protein by
these cells.
Discussion
These experiments demonstrate that IGF-I suppresses secre-
tion of both IGF-BP-1 and a 24,000-Mr form of IGF-BP by
Figure 6. Inhibition of
250 relaxin-mediated effects
200 by cycloheximide. De-
cidual cultures exposed
C 150 over a 96-h period to ei-
co S//Mther control medium, or
o100 o medium supplemented
50 with relaxin (100
vxz/FA r, V77 ng/ml), cycloheximide
CONTROL CYCLO RLX RLX. (50 ;g/ml), or the com-
CYCLO bination of the two
were sampled daily and
assayed for IGF-BP- 1. Each point represents the mean±SEM of trip-
licate 96-h samples. Control vs. relaxin, P < 0.001.






-69 K regulation of the three
forms of IGF-BP se---46 K creted by human decid-
ual cells. 20-,gl samples
30 K of 120 h conditioned
- - ~ media from decidual
-21.5 K cultures exposed to
-I 4 K IGF-I, insulin, or re-
laxin were electropho-
resed through SDS
1 2 3 4 polyacrylamide gels,
transferred to nitrocellulose filters, and probed with '251-IGF-I
(100,000 cpm/cc). Lane I shows the three forms of IGF-BP detected
in control medium. Lanes 2, 3, and 4 show the differential effects of
IGF-I, insulin, and relaxin, respectively, on the relative intensity of
the 24,000- and 30,000-M, bands. Defined molecular weight stan-
dards were run in a parallel lane.
human decidual cells in culture. Suppression of the 24- and
30,000-Mr forms of IGF-BP by IGF-I is contrasted with
IGF-I-mediated effects in other systems. For example, Clem-
mons et al. have demonstrated that IGF-I stimulates IGF-BP
secretion from three distinct muscle cell types (29) and specifi-
cally stimulates IGF-BP secretion by human fibroblasts (21).
Binoux and Lasarre have shown that IGF-I stimulates the se-
cretion of binding activity from liver explants (28). Similarly,
induction of IGF-BP-2 and IGF-BP-3 secretion in serum fol-
lowing subcutaneous IGF-I infusion has been demonstrated in
hypox and diabetic rat models and in normal man (45). In
contrast, IGF-I and insulin have been shown to suppress IGF-
BP- 1 secretion by Hep G2 cells in culture (30).
The reason for suppression ofdecidual IGF-BP- 1 secretion
by IGF-I is unclear. The IGF-BP RIA is a sensitive assay of
both bound and unbound IGF-BP, and is unaffected by the
presence of IGF-I in the media (40). Therefore, the effect is not
mediated by changes in IGF-I saturation, which is confirmed
by gel electrophoresis data. These findings, therefore, strongly
support a cell type-specific response to IGF-I exposure.
The functional significance of suppression of IGF-BP- 1 se-
cretion in decidual cell physiology has not been clearly de-
fined. IGF-BP-1 has high affinity for IGF-I and has been
shown to enhance the cellular DNA synthetic response of fi-
broblasts and smooth muscle cells to IGF-I (1 1). If decidual
IGF-BPs similarly potentiate in utero IGF-I effects on these
cell types, suppression of IGF-BP-1 secretion by IGF-I may
serve as a negative feedback control mechanism for modulat-
ing cellular growth in this system. Alternatively, decidual
IGF-BP has been shown to inhibit 1251I-IGF-I binding to both
placental and endometrial receptors (46). In this situation,
suppression of binding protein secretion by IGF-I would allow
for a less complex and more direct growth factor-receptor in-
teraction. We recognize, however, that when decidual cells are
removed from their physiologic microenvironment, their re-
sponse to various secretogogues may be altered from the re-
sponse that occurs under in vivo conditions.
Insulin, like IGF-I, also inhibited release ofIGF-BP- 1. This
inhibition does not appear to be the result of preferential deg-
radation of IGF-BP-1 into the 24,000-Mr form since the
24,000-Mr protein is not detectable by Western blotting with
the polyclonal antisera used in the IGF-BP- 1 RIA (34). Insulin
has been shown to have both stimulatory effects on IGF-BP
secretion in myocytes (29) and inhibitory effects on IGF-BP
secretion from cultures Hep G2 cells (30). Likewise, insulin
appears to be a potent suppressor of IGF-BP secretion in vivo.
In this system, however, insulin appears to be affecting decid-
ual cell IGF-BP-l secretion in a manner analogous to IGF-I.
Both IGF-I and insulin have a similar IC50 value for IGF-
BP-1 suppression (e.g., 25 ng/ml). This insulin concentration
is higher than would be necessary to activate insulin receptors,
but lower than that necessary to bind to type I IGF receptors.
This suggests that the insulin effect could be mediated through
a distinct receptor subtype. Recently, Moxham et al. have de-
scribed the existence ofa unique receptor subtype composed pf
one a-,B subunit from the type I IGF receptor and one from the
insulin receptor (47). The insulin response noted above is con-
sistent with a model whereby insulin effects are mediated via
this unique receptor.
Significant inhibition of IGF-BP-l secretion was not de-
tected at IGF-I concentrations below 25 ng/ml. It is possible
that release of IGF-BPs may be attenuating the suppressive
effects of IGF-I at lower concentrations. At higher concentra-
tions, however, IGF-I consistently induced a greater degree of
inhibition than the same concentration ofinsulin. a-IR3 inhib-
ited - 1/3 of the IGF-I response, suggesting that this portion of
the total IGF-I response is mediated through the type I IGF
receptor. The a-IR3 concentration used in these experiments
was fivefold greater than that shown to inhibit 83% of the
specific binding of IGF-I to decidual type I receptors (48).
Therefore, the receptor subtype mediating the remaining two-
thirds of the IGF-I response that is not inhibited by a-IR3 has
not been determined.
Unlike IGF-I, insulin significantly stimulated release ofthe
24,000 Mr IGF-BP. Discordant hormonal regulation of multi-
ple forms of IGF-BP from a single cell type has not previously
been reported. This discordant response suggests that each
species of binding protein may have distinct functional roles
that need to be coordinated. Further studies are required to
determine the range ofcell types that respond to insulin in this
manner.
The effects of relaxin on IGF-BP- I secretion have not been
previously described. Extraluteal localization of relaxin to
human endometrial stromal cells and decidual cells has been
noted (49-52), and the uterus is a major target tissue for re-
laxin effects on tissue growth and myometrial contractility
(53-56). The present observations suggest that relaxin may
also be involved in the regulation ofIGF-BP secretion by uter-
ine tissues through autocrine or paracrine mechanisms. In
700 Figure 8. Effect of
600 IGF-I and insulin on re-
500
laxin stimulated IGF-
E 500 g BP-1 release. Mono-
400 layer cultures were ex-
300 posed for 96 h to IGF-I,
O200 t X insulin, relaxin (100200
ng/ml each), IGF-I
100 + relaxin, or insulin
0 _F I r. ,,1+ relaxin. Triplicate
CON RLX IGF-I INS RLX RLX cultures were assayed
IGF-I INS for IGF-BP- I at 24 h
intervals and the 96-h results are presented here as a mean±SEM.
The effects of relaxin, IGF-I, and insulin were significantly different
from control (P < 0.001 in each instance). IGF-I and insulin inhib-
ited the stimulation by relaxin (P < 0.001 in each instance).
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contrast to IGF-I and insulin, relaxin caused a marked in-
crease in the release ofboth the 24,000- and 30,000-Mr species.
Whether such stimulation might potentiate or neutralize IGF-I
action is unclear, but the observation opens up the possibility
that relaxin could modulate tissue IGF responsiveness.
The potential interaction of relaxin with IGF-I or insulin
receptors is -less well characterized. Although relaxin has only
- 25% amino acid sequence homology with the insulin-like
class of growth factors (52, 53), striking similarities of tertiary
structure exist, potentially allowing for receptor cross-reactiv-
ity. Purified relaxin does not appreciably compete with bind-
ing of radiolabeled insulin to insulin receptors on IM-9 lym-
phocytes, leukocytes, or adipocytes (57), but the interaction of
relaxin with the type I IGF receptor has not been determined.
The striking stimulation seen in this study, however, in con-
trast to the inhibition of IGF-I and insulin, suggests that the
signal allowing for this differential regulation of IGF-BP-l se-
cretion is transduced through a distinct receptor subtype.
We have previously demonstrated that activation of ade-
nylate cyclase stimulates the secretion of IGF-BP-l from the
decidua (34). Interestingly, this intracellular signalling path-
way has been implicated as a second messenger for relaxin in
other systems (58-60). Since both IGF-I and insulin block
both the relaxin- and cAMP-induced stimulation of decidual
IGF-BP- I synthesis, it is possible that cAMP may be mediating
the relaxin signal.
In summary, a class of structurally homologous growth
factors appears to play a unique role in the regulation of de-
cidual IGF-BP secretion in vitro. The demonstration of local-
ized in utero production of all three hormones suggests that
this may represent a system of autocrine or paracrine regula-
tory control.
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